Article
Nanoscience & Nanotechnology
Lejiao Jia, Huatian Yang, Dandan Zheng, Jingjing Ye, Qian Zhou, Genjv Li, Ying Zhou, Xinyu Yang, Jinting Liu, Feng Ye, Yuliang Song, Daoxin Ma, Chunyan Ji
Summary: This study synthesized a mercaptopropionic acid-substituted derivative of Ara-C and used it as a trigger to fabricate a smart cytarabine and venetoclax-coloaded nanoparticle (AV-NP) with redox-responsive drug release, rapid uptake by leukemia cells, and long circulation retention. The AV-NP showed higher antileukemia activity and better safety in the hematologic system compared to free drugs, and significantly improved the therapeutic effect on orthotopic AML mice in vivo.
ACS APPLIED MATERIALS & INTERFACES
(2023)
Article
Oncology
Meghali Goswami, Gege Gui, Laura W. Dillon, Katherine E. Lindblad, Julie Thompson, Janet Valdez, Dong-Yun Kim, Jack Y. Ghannam, Karolyn A. Oetjen, Christin B. Destefano, Dana M. Smith, Hanna Tekleab, Yeusheng Li, Pradeep Dagur, Thomas Hughes, Jennifer L. Marte, Jaydira del Rivero, Joanna Klubo-Gwiezdzinksa, James L. Gulley, Katherine R. Calvo, Catherine Lai, Christopher S. Hourigan
Summary: This study aimed to investigate the feasibility and efficacy of the combination of PD-1 blockade and hypomethylating therapy in patients with R-AML. The results showed that this combination therapy achieved disease stability or better response in some patients. Moreover, clonal T cell expansions and immunological changes were observed during treatment, which may be associated with treatment-related adverse events.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Jack M. Su, Lindsay B. Kilburn, David B. Mansur, Mark Krailo, Allen Buxton, Adesina Adekunle, Amar Gajjar, Peter C. Adamson, Brenda Weigel, Elizabeth Fox, Susan M. Blaney, Maryam Fouladi
Summary: The phase I/II trial of vorinostat in children with newly diagnosed DIPG showed that the regimen of vorinostat given concurrently with radiation followed by vorinostat monotherapy was well tolerated but did not significantly improve outcomes.
Article
Hematology
Jose Tinajero, Dat Ngo, Amandeep Salhotra, Paul Koller
Summary: This study presents a CCE (cladribine, cytarabine, and etoposide) based regimen for relapsed/refractory acute myeloid leukemia (AML) patients. The regimen offers a potential option for patients who cannot tolerate anthracycline.
ACTA HAEMATOLOGICA
(2023)
Article
Oncology
Aida Vitkeviciene, Giedre Skliute, Andrius Zucenka, Veronika Borutinskaite, Ruta Navakauskiene
Summary: The study aimed to identify new potential prognostic markers for acute myeloid leukemia (AML) treatment. The analysis showed that refractory AML patients had significantly higher expression of oncogenic MYC and WT1 genes, as well as metabolic IDH1 gene. On the other hand, the expression of cell cycle inhibitor CDKN1A (p21) gene was significantly lower in refractory patients. Additionally, refractory patients had higher expression of HDAC2 and TET1 genes, and lower expression of KAT6A and GATAD2A genes compared to treatment responsive patients. The study also suggested that combining epigenetic modulation with standard treatment may be beneficial.
Article
Hematology
Marina Y. Konopleva, Christoph Roellig, Jamie Cavenagh, Dries Deeren, Larisa Girshova, Juergen Krauter, Giovanni Martinelli, Pau Montesinos, Jonas A. Schaefer, Oliver Ottmann, Mario Petrini, Arnaud Pigneux, Alessandro Rambaldi, Christian Recher, Rebeca Rodriguez-Veiga, David Taussig, Norbert Vey, Sung-Soo Yoon, Marion Ott, Susanne Muehlbauer, Benjamin M. Beckermann, Olivier Catalani, Magali Genevray, Kirsten Mundt, Candice Jamois, Pierre Fenaux, Andrew H. Wei
Summary: A study evaluating the efficacy and safety of the MDM2 antagonist idasanutlin plus cytarabine in patients with relapsed/refractory acute myeloid leukemia found that this combination did not improve overall survival or complete remission rates, despite an increased overall response rate.
Article
Oncology
Chengtao Zhang, Da Gao, Xiaohong Wang, Xiuli Sun, Yan Yan, Yan Yang, Jingjing Zhang, Jinsong Yan
Summary: This study investigated the effectiveness and safety of a new induction therapy (BHA) for patients with refractory/relapsed acute myeloid leukemia (R/R AML). The results showed a CR/CRi rate of 38.1% after one course of BHA and a higher CR/CRi rate of 66.7% in patients with FLT3 mutation. BHA chemotherapy regimen was found to be safe and tolerable for R/R AML patients, especially those with FLT3 mutation.
FRONTIERS IN ONCOLOGY
(2023)
Article
Hematology
Ewa Paszkiewicz-Kozik, Wojciech Michalski, Michal Taszner, Monika Mordak-Domagala, Joanna Romejko-Jarosinska, Wanda Knopinska-Posluszny, Jacek Najda, Anna Borawska, Monika Chelstowska, Monika Swierkowska, Anna Dabrowska-Iwanicka, Agata Malenda, Agnieszka Druzd-Sitek, Robert Konecki, Beata Kumiega, Michal Osowiecki, Beata Ostrowska, Tomasz Szpila, Marcin Szymanski, Lukasz Targonski, Katarzyna Domanska-Czyz, Lidia Poplawska, Sebastian Giebel, Andrzej Lange, Andrzej Pluta, Jan Maciej Zaucha, Grzegorz Rymkiewicz, Jan Walewski
Summary: This study evaluated the efficacy and safety of ofatumumab in combination with iphosphamide, etoposide, and cytarabine (O-IVAC) in relapsed or progressing diffuse large B-cell lymphoma (DLBCL) patients. The overall response rate (ORR) for O-IVAC was 54.5%, with a median progression-free survival (PFS) and event-free survival (EFS) of 16.3 months each, and a median overall survival (OS) of 22.7 months. Age, ECOG performance status, and prior therapy lines were independent predictors of survival.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Review
Oncology
Serena Brancati, Lucia Gozzo, Giovanni Luca Romano, Calogero Vetro, Ilaria Dulcamare, Cinzia Maugeri, Marina Parisi, Laura Longo, Daniela Cristina Vitale, Francesco Di Raimondo, Filippo Drago
Summary: This review summarizes the evidence on the use of Venetoclax (VEN) regimens in the treatment of relapsed/refractory acute myeloid leukemia (AML) patients. Despite the development of new therapeutic strategies, there is still a high medical need for improved treatments in this patient population.
Review
Oncology
Anna Wawruszak, Lidia Borkiewicz, Estera Okon, Wirginia Kukula-Koch, Syeda Afshan, Marta Halasa
Summary: Breast cancer remains a challenging malignancy with varying responses to therapy, requiring the development of new active agents to improve the current treatment regimens. Vorinostat (SAHA) shows promise in the therapy of different histological subtypes of breast cancer, either alone or in combination with other anticancer agents, based on preclinical and clinical trials data.
Article
Hematology
Nikhil Raghuram, Daisuke Hasegawa, Kentaro Nakashima, Syaza Rahman, Evangelia Antoniou, Torjus Skajaa, Pietro Merli, Anupam Verma, Karen R. Rabin, Catherine Aftandilian, Rishi S. Kotecha, Daniel Cheuk, Kirsi Jahnukainen, Alexandra Kolenova, Walentyna Balwierz, Alice Norton, Maureen O'Brien, Sonia Cellot, Ashley Chopek, Nira Arad-Cohen, Bianca Goemans, Marta Rojas-Vasquez, Hany Ariffin, Jack Bartram, E. Anders Kolb, Franco Locatelli, Jan-Henning Klusmann, Henrik Hasle, Bryan Mcguire, Afia Hasnain, Lillian Sung, Johann Hitzler
Summary: Children with Down syndrome are at a higher risk of developing acute myeloid leukemia, and those who relapse or have refractory ML-DS have a poor prognosis. Current treatment options are limited, and hematopoietic stem cell transplantation, duration of first complete remission, and achieving remission after relapse are associated with improved survival.
Article
Oncology
Jorge Labrador, Miriam Saiz-Rodriguez, Dunia de Miguel, Almudena de Laiglesia, Carlos Rodriguez-Medina, Maria Belen Vidriales, Manuel Perez-Encinas, Maria Jose Sanchez-Sanchez, Rebeca Cuello, Alicia Roldan-Perez, Susana Vives, Gonzalo Benzo-Callejo, Mercedes Colorado, Maria Garcia-Fortes, Maria Jose Sayas, Carmen Olivier, Isabel Recio, Diego Conde-Royo, Alvaro Bienert-Garcia, Maria Vahi, Carmen Munoz-Garcia, Cristina Seri-Merino, Mar Tormo, Ferran Vall-llovera, Maria-Angeles Foncillas, David Martinez-Cuadron, Miguel Angel Sanz, Pau Montesinos
Summary: The effectiveness of venetoclax (VEN) in relapsed or refractory acute myeloid leukemia (RR-AML) has not been well established. This study found that the combination of venetoclax with azacitidine had a higher complete remission rate compared to combination with decitabine and low-dose cytarabine. Mutated NPM1 was associated with increased complete remission rate.
Article
Oncology
Hui Zhang, Pengfei Wang, Zhuoyan Li, Yingyi He, Wenting Gan, Hua Jiang
Summary: The study tested the safety and efficacy of anti-CLL1 CAR T-cell therapy in pediatric patients with R/R-AML, showing promising results with a high rate of complete remission and minimal residual disease negativity in patients. The therapy was well tolerated with low-grade and manageable adverse events, indicating the potential of autologous anti-CLL1 CAR T-cell therapy as a safe and efficient treatment option for children with R/R-AML. Further investigation is warranted to explore its full potential.
CLINICAL CANCER RESEARCH
(2021)
Article
Medicine, General & Internal
Matteo Piccini, Sofia Pilerci, Marta Merlini, Pietro Grieco, Barbara Scappini, Sara Bencini, Benedetta Peruzzi, Roberto Caporale, Leonardo Signori, Fabiana Pancani, Alessandro Maria Vannucchi, Giacomo Gianfaldoni
Summary: For patients with relapsed/refractory acute myeloid leukemia, venetoclax-based regimens show promise in achieving composite complete response rates, with particular benefit seen in patients with NPM1 mutations. The possibility of undergoing transplant in intention-to-treat patients was 54%.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Multidisciplinary Sciences
Nichole Owen, Irina G. Minko, Samantha A. Moellmer, Sydney K. Cammann, R. Stephen Lloyd, Amanda K. McCullough
Summary: Human clinical trials suggest that inhibition of enzymes in the DNA base excision repair (BER) pathway, such as PARP1 and APE1, can be useful in anticancer strategies when combined with certain DNA-damaging agents. Specifically, in acute myeloid leukemia (AML), AML cell lines deficient in OGG1 have enhanced sensitivity to cytarabine (Ara-C) treatment. This enhanced cytotoxicity is likely due to the insertion of Ara-C opposite unrepaired 8-oxo-dG in OGG1-deficient AML cells.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Oncology
Jennifer R. Eads, Jan H. Beumer, Lavinia Negrea, Julianne L. Holleran, Sandra Strychor, Neal J. Meropol
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2016)
Article
Oncology
Shivaani Kummar, Alice Chen, Martin Gutierrez, Thomas D. Pfister, Lihua Wang, Christophe Redon, William M. Bonner, William Yutzy, Yiping Zhang, Robert J. Kinders, Jiuping Ji, Deborah Allen, Joseph M. Covey, Julie L. Eiseman, Julianne L. Holleran, Jan H. Beumer, Larry Rubinstein, Jerry Collins, Joseph Tomaszewski, Ralph Parchment, Yves Pommier, James H. Doroshow
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2016)
Article
Oncology
Martin J. Edelman, Rena Lapidus, Josephine Feliciano, Miroslav Styblo, Jan H. Beumer, Tao Liu, Jogarao Gobbru
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2016)
Correction
Oncology
Martin J. Edelman, Rena Lapidus, Josephine Feliciano, Miroslav Styblo, Jan H. Beumer, Tao Liu, Jogarao Gobburu
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2016)
Article
Oncology
James J. Lee, Jabed Seraj, Kenichiro Yoshida, Hirokazu Mizuguchi, Sandra Strychor, Jillian Fiejdasz, Tyeler Faulkner, Robert A. Parise, Patrick Fawcett, Laura Pollice, Scott Mason, Jeremy Hague, Marie Croft, James Nugteren, Charles Tedder, Weijing Sun, Edward Chu, Jan Hendrik Beumer
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2016)
Article
Oncology
Charles A. Kunos, Edward Chu, Jan H. Beumer, Mario Sznol, S. Percy Ivy
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2017)
Review
Oncology
James J. Lee, Jan H. Beumer, Edward Chu
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2016)
Article
Oncology
Brian F. Kiesel, Robert A. Parise, Jianxia Guo, Donna M. Huryn, Paul A. Johnston, Raffaele Colombo, Malabika Sen, Jennifer R. Grandis, Jan H. Beumer, Julie L. Eiseman
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2016)
Article
Oncology
Eve T. Rodler, Brenda F. Kurland, Melissa Griffin, Julie R. Gralow, Peggy Porter, Rosa F. Yeh, Vijayakrishna K. Gadi, Jamie Guenthoer, Jan H. Beumer, Larissa Korde, Sandra Strychor, Brian F. Kiesel, Hannah M. Linden, John A. Thompson, Elizabeth Swisher, Xiaoyu Chai, Stacie Shepherd, Vincent Giranda, Jennifer M. Specht
CLINICAL CANCER RESEARCH
(2016)
Article
Oncology
Elizabeth T. Chang, Palak R. Parekh, Qingyuan Yang, Duc M. Nguyen, France Carrier
Article
Chemistry, Analytical
Brian F. Kiesel, Robert A. Parise, Alvin Wong, Kiana Keyvanjah, Samuel Jacobs, Jan H. Beumer
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
(2017)
Article
Biochemical Research Methods
Katherine Coburn, Zephan Melville, Ehson Aligholizadeh, Braden M. Roth, Kristen M. Varney, France Carrier, Edwin Pozharski, David J. Weber
ACTA CRYSTALLOGRAPHICA SECTION F-STRUCTURAL BIOLOGY COMMUNICATIONS
(2017)
Article
Dermatology
Rajeshwar N. Srivastava, Mukesh K. Dwivedi, Amit K. Bhagat, Saloni Raj, Rajiv Agarwal, Abhijit Chandra
INTERNATIONAL WOUND JOURNAL
(2016)
Article
Biochemistry & Molecular Biology
Eduardo Solano-Gonzalez, Katherine M. Coburn, Wenbo Yu, Gerald M. Wilson, Elmar Nurmemmedov, Santosh Kesari, Elizabeth T. Chang, Alexander D. MacKerell, David J. Weber, France Carrier
Summary: The chemical probes identified in this study target hnRNP A18 RNA Recognition Motif (RRM), leading to disruption of hnRNP A18-RNA interactions and downregulation of key proteins, ultimately inhibiting cancer cell proliferation without affecting normal cell viability. The findings highlight the potential of post-transcriptional regulation of immune checkpoints as a therapeutic strategy in cancer treatment.
NUCLEIC ACIDS RESEARCH
(2021)
Review
Oncology
Rahul A. Parikh, Leonard J. Appleman, Jan H. Beumer, Ewa Matczak, Edward Chu
CLINICAL GENITOURINARY CANCER
(2017)